中大剂量阿糖胞苷治疗儿童急性髓系白血病40例疗效观察及预后相关因素分析

《中大剂量阿糖胞苷治疗儿童急性髓系白血病40例疗效观察及预后相关因素分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20123051HebeiMedicalUniversity硕士学位论文专业学位中大剂量阿糖胞苷治疗儿童急性髓系白血病40例疗效观察及预后相关因素分析研究生：王俊捷导师：张宝玺教授专业：儿科学二级学院：第二医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师（或指导小组）的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单位河北医科大学，试

2、验材料、原始数据、申报的专利等知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：导师签章:二级学院领美盖章:河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果，指导教师对此进行了审定。本论文由本人独立撰写，文责自负。研究生签名：L导师签章：<5^i年3叫曰目录中文摘要······································································

3、········1英文摘要··············································································4英文缩写··············································································8研究论文中大剂量阿糖胞苷治疗儿童急性髓系白血病40例疗效观察及预后相关因素分析前言……………………………………………………………………12材料与方法……………………………………………………

4、………12结果·············································································16附图·············································································19附表·············································································21讨论···················

5、··························································25结论·············································································29参考文献·······································································30综述阿糖胞苷治疗儿童白血病的现状和发展····························33致谢

6、··················································································49个人简历············································································50中文摘要中大剂量阿糖胞苷治疗儿童急性髓系白血病40例疗效观察及预后相关因素分析摘要目的:使用回顾性队列研究方法，收集并整理急性髓细胞白血病（Acutemyeloidleukemia,AML）患儿的生物学特点

7、、临床表现及生存情况。通过对所收集的资料进行统计学描述及分析，探讨采用中大剂量阿糖胞苷（ID/HD-Ara-C）治疗儿童急性髓系白血病（AML）的疗效及行相关危险因素分析。方法:回顾性的分析2004年12月至2015年1月于河北医科大学第二医院儿科血液专业住院的40例AML患儿。1纳入标准：①年龄小于或等于14岁②符合儿童AML诊断标准。诊断依据《儿童急性髓细胞白血病诊疗建议---2006年》。排除标准：①急性早幼粒细胞白血病（APL）②未经我院初治的AML患儿③未给予ID/HD-Ara-C方案化疗的AML患儿。2设计病史摘录表。系

8、统摘录AML患儿的性别、发病年龄、FAB分型、诱导缓解方案及疗程、发病时间及化疗结束时间、发病时WBC、HGB、PLT数值、骨髓抑制开始及结束时间、化疗后不良反应、血液制品输注等指标。3设计随访表，收集统计AML患儿的生存情况及计算生